Repromedix Corp., the leading national diagnostic laboratory for advanced reproductive testing, announced today that Dr. Michael J. Burns has been appointed Chief Executive Officer.
“We are delighted that we were able to attract Dr. Burns to Repromedix,” said Jack Davis, Chairman of the Board. With over 25-years experience growing international pharmaceutical and healthcare companies, Dr. Burns brings extensive senior and general management experience in the critical areas of medical research and development, corporate and business development, product licensing and sales force delivery and marketing.”
Dr. Burns comes to Repromedix after having served more than ten years as the President and Chief Operating Officer of Ferndale Laboratories, a leader in the manufacturing and marketing of pharmaceutical products and medical devices. Having joined Ferndale in 1992, Dr. Burns also served as the President of the company’s Pharmaceutical Division and Vice President of Corporate Development. Prior to Ferndale, Dr. Burns held senior management and leadership positions with Yamanouchi Europe B.V., Smith, Kline & French Pharmaceuticals Ltd., and Napp Laboratories Ltd.
“The increasing number of women seeking to have children later in life has significantly contributed to the development of sophisticated and innovative diagnostic techniques in reproductive medicine,” said Paul Kowalski, President and Vice President of Sales. “Repromedix has grown from a pioneer to national leader in infertility diagnostics. We look forward to leveraging Dr. Burns’ industry experience and expertise as we continue to meet the growing need for valuable medical and genetic information that can contribute to the attainment of parenthood for so many.”
“I couldn’t be more excited to join the incredible team of infertility professionals at Repromedix,” said Dr. Michael J. Burns. “I am especially attracted to Repromedix’ decade-long passion for helping doctors help couples start families. I share deeply the company’s entrepreneurial spirit, its commitment to excellence and its vision for future growth and medical partnership opportunities. I look forward to contributing to the company’s continued growth and success.”
A British native, Dr. Burns holds a postgraduate degree in Pharmacology from the University of Nottingham and an undergraduate degree from the University of Reading in Physiology, Biochemistry and Chemistry.
Repromedix (repromedix.com) is the leading national diagnostic laboratory for advanced reproductive testing. By taking an interdisciplinary approach to clinical infertility testing that encompasses endocrinology, immunology and genetics, Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding complex problems of reproductive failure. Since its inception in 1995, the company has assisted more than 45,000 patients by conducting over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility and unexplained infertility.